Epidermal growth factor receptor (EGFR), which belongs to the receptor tyrosine kinase family,[8] is important for drug resistance, cancer stem cells, and metastasis in different types of cancer.[9] EGFR expression in solid tumors, including breast cancer, is 20–50‐fold higher than that reported in normal tissues,[10] and high EGFR expression is found in 69% of TNBC.[11] Therefore, treatment targeting EGFR, including inhibitors of EGFR (e.g., tyrosine kinase inhibitors, TKIs) and mAbs have been taken efforts. The gene discussed is EGFR; the disease is breast carcinoma.